HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

ATRIAL FIBRILLATION AND HYPERTENSION IN THYROID DISEASES

DOI: https://doi.org/10.29296/25877305-2019-01-14
Issue: 
1
Year: 
2019

L. Khidirova(1), Candidate of Medical Sciences; Professor D. Yakhontov(1), MD; S. Zenin(2); V. Maksimov(3) 1-Novosibirsk State Medical University; 2-Novosibirsk Regional Cardiology Clinical Dispensary; 3-Resarch Institute of Therapy and Preventive Medicine, Branch, Federal Research Center «Institute of Cytology and Genetics, Siberian Branch. Russian Academy of Sciences», Novosibirsk

The paper assesses polymorphism rs1378942 gene CSK and the features of the course of the disease in patients with hypertension and atrial fibrillation (AF) concurrent with thyroid diseases and their role in the progression of AF.

Keywords: 
cardiology
atrial fibrillation
hypertension
thyrotoxicosis
hypothyroidism



References: 
  1. Heeringa J., Hoogendoorn E., Van der Deure W. et al. High-normal thyroid function and risk of atrial fibrillation the Rotterdam Study // Arch. Intern. Med. – 2008; 168 (20): 2219–24. DOI:10.1001/archinte.168.20.2219.
  2. Belluzzi F., Sernesi L., Preti P. et al. Prevention of recurrence lone atrialfibrillation by the angiotensin II converting Enzyme inhibitor ramiprilinnormotensive patients // JACC. – 2009; 53: 24–9. DOI: 10.1016/j.jacc.2008.08.071
  3. Boss Ch., Lip G. Targeting the renin-angiotensin-aldosterone system inatrial fibrillation: from pathology to clinical trials // J. Hum. Hypertens. – 2005; 19: 855–9. DOI:10.1038/jhh.2014.125
  4. Lip G., Coca A. Aconsensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and SociedadLatinoamericana de Estimulaci_onCard_iaca y Electrofisiologia (SOLEACE), 2016
  5. Ahmad T., Fiuzat M., Neely, B. et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure // JACC Heart Failure. – 2014; 2 (3): 260–8. DOI: 10.1016/j.jchf.2013.12.004
  6. Ertugrul D., Yavuz B., Ata N. et al. Decreasing brain natriuretic peptide levels after treatment for hyperthyroidism // Endocr. J. – 2009; 56 (9): 1043–8. DOI:10.1507/endocrj.K09E-159
  7. Vasan R., Magnani J., Ellinor P. et al. Galectin 3 and incident atrial fibrillation in the community // Am. Heart J. – 2014; 167 (5): 729–34. https://escholarship.umassmed.edu/umccts_pubs/17/
  8. Ionin V.A., Listopad O.V., Nifontov S.E. i dr. Galektin-3 u pacientov s metabolicheskim sindromom i fibrillyaciey predserdiy // Arterial`naya gipertenziya. – 2014; 5: 101–8 [Ionin V.A., Listopad O.V., Nifontov S.E. et al. Galectin-3 in patients with metabolic syndrome and atrial fibrillation // Arterial Hypertension J. – 2014; 5: 101–8 (in Russ.)]. https://doi.org/10.18705/1607-419X-2014-20-5-462-469
  9. Mansourian A. A review on cardiovascular diseases originated from subclinical hypothyroidism // Pak. J. Biol. Sci. – 2012; 15 (2): 58–67.
  10. Schmidt M., Schicha H. Thyroid disorders // Versicherungsmedizin. – 2011; 63 (4): 176–9.
  11. Corvilain B. Subclinical hyperthyroidism: from diagnosis to treatment. Rev. Med. Brux. – 2012; 33 (4): 241–5.
  12. Hen K., Czarnywojtek A., Stangierski A. et al. Effect of amiodarone on the thyroid function and safety of the therapy – what's new // Przegl. Lek. – 2012; 69 (10): 1135–9.
  13. Collet T., Gussekloo J., Bauer D. et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality // Arch. Intern. Med. – 2012; 172 (10): 799–809. DOI:10.1001/archinternmed.2012.402
  14. Duntas L., Brenta G. The effect of thyroid disorders on lipid levels and metabolism // Med. Clin. North Am. – 2012; 96 (2): 269–81. DOI:10.1016/j.mcna.2012.01.012
  15. Ari H., Girdogan M., Erdogan E. et al. Short-term outcome of early electrical cardioversion for atrial fibrillation in hyperthyroid versus euthyroid patients // Cardiol. J. – 2012; 19 (1): 53–60.
  16. Patane S., Marte F. Revelation of changing axis deviation at the end of atrial fibrillation associated with endogenous subclinical hyperthyroidism // Sturiale Intern. J. Cardiol. – 2012; 155 (1): 1–4. DOI:10.1016/j.ijcard.2009.10.001
  17. Fadeev V.V. Bolezn` Greyvsa // Rus. med. zhurn. – 2002; 27 (171): 1262–5 [Fadeyev V.V. Bolezn' Greyvsa // Rus. med. zhurn. – 2002; 27 (171): 1262–5 (in Russ.)].
  18. Niafar M., Toufan M., Ghafoori S. et al. Subclinical hypothyroidism effects on cardiac function // Pak. J. Biol. Sci. – 2009; 12 (15): 1056–62.
  19. Nikulina S.Yu., Shul`man V.A., Kuznecova O.O. i dr. Kliniko-geneticheskie osobennosti fibrillyacii predserdiy // Rac. farmakoter. v kardiol. – 2008; 4 (2): 13–8 [Niculina S.Yu., Sulman V.A., Kuznecova O.O. et al. Clinical and genetic features of atrial fibrillation // Racional’najafarmakoterapija v kardiologii. – 2008; 4 (2): 13–8 (in Russ.)].